The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

USPSTF breast cancer screening guidelines are clear, concise; now let’s address gaps in quality

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

This week, the U.S. Preventive Services Task Force published a new draft guideline on breast cancer screening.1 The task force is considered the most rigorous and orthodox authority on the interpretation and application of the medical literature.The panel is widely respected for its expertise in epidemiology, screening, clinical trials interpretation, and structured reviews of the...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Otis W. Brawley, MD, MACP, FRCP(L)
Bloomberg Distinguished Professor of Oncology and Epidemiology, Johns Hopkins University
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Enhertu demonstrates improvement in invasive DFS in HER2+ breast cancer after neoadjuvant therapy

Positive high-level results showed Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival versus trastuzumab emtansine in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence, according to a planned interim analysis of the DESTINY-Breast05 phase III trial. 
Byline
Otis W. Brawley, MD, MACP, FRCP(L)
Bloomberg Distinguished Professor of Oncology and Epidemiology, Johns Hopkins University
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account